euglycemic hyperinsulinemic clamp
- Sensitivity (15%) sufficient to detect a statistically significant impact of your compound on insulin resistance.
- Essential and robust data for your records: the isotopic glucose enrichment procedure is a unique solution giving access to hepatic glucose production, glycolysis and glycogen synthesis.
- Specific mechanisms targeted by your compound: the insulin dose is chosen to prioritize either hepatic glucose production or peripheral glucose utilization.
Description and parameters
A gold-stantard method to assess insulin sensitivity in vivo
The hyperinsulinemic euglycemic clamp using radioactive labeled tracers is a unique solution for distinguishing your compound from your competitors’ products.
- Two-step euglycemic hyperinsulinemic clamp:
Provides a global picture of hepatic and peripheral insulin resistance in a single animal: offers an integrated evaluation of mechanisms which are not animal-dependent, saving animals, time, and money.
- Hyperglycemic hyperinsulinemic clamp:
Provides unique whole body data on insulin-regulated hepatic glycogen synthesis: this technique places the focus on hepatic glycogen synthesis, which is strongly stimulated in hyperglycemic conditions.
- Whole-body glucose utilization rate (TO)
- Hepatic glucose production (HGP)
- Glucose infusion rate (GIR)
- Whole-body glycolysis rate.
- Whole-body glycogen synthesis rate
- Individual tissue glucose uptake assay for identifying specific tissues targeted by your compound, thereby identifying unexpected adverse effects and additional benefits, or for stratifying heterogeneous patient populations for clinical trials.
- FFA turnover technique to complete the overview of your drug compound’s impact on whole-body insulin sensitivity and lipid metabolism.